Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Party season approaches; but first, conferences.
